InvestorsHub Logo
Followers 110
Posts 6480
Boards Moderated 0
Alias Born 05/01/2003

Re: louisa post# 21056

Wednesday, 12/02/2009 2:41:24 PM

Wednesday, December 02, 2009 2:41:24 PM

Post# of 92948
louisa and woodrow,

louisa,
I believe the last Company statements on the issues you brought up were in this PR from March(below)

Woodrow, thank you for the news update. FED funding now begins on hESC's
approved lines:
http://grants.nih.gov/stem_cells/registry/current.htm
pending lines:
http://grants.nih.gov/stem_cells/registry/pending.htm


"We believe that the issue of whether the Federal government should fund the destruction of human embryos has become unnecessarily politicized," said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. "ACTC has repeatedly demonstrated that it can develop stem cell lines without the destruction of the embryo utilizing its single cell blastomere technology. While we are fortunate that we have been able to secure financing to take our RPE program into the clinic, we feel that once the Federal government and scientific communities realize that it is possible, through the use of our technology platform, to satisfy the requirements of both conservatives and liberals, the Company should be able to secure significant federal funding to utilize this technology for research and development. Although we have previously announced receipt of small grants from the NIH, we have been rebuffed in our efforts to utilize this particular technology in federally funded programs. We offer a unique solution to a widely-debated problem which should under the current environment facilitate federal acceptance and funding for the application of our technology to new and existing research and development programs."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=36225972&txt2find=rebuffed
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.